Asunto(s)
Analgésicos Opioides/administración & dosificación , Buprenorfina/administración & dosificación , Naloxona/administración & dosificación , Tilidina/administración & dosificación , Tramadol/administración & dosificación , Administración Cutánea , Estudios de Seguimiento , Humanos , Movimiento , Dimensión del Dolor , Cooperación del Paciente , Premedicación , Calidad de Vida , Factores de Tiempo , Resultado del TratamientoRESUMEN
The transdermal 7-day buprenorphine matrix patch provides a constant and user-friendly pain management when chronic musculoskeletal pain requires opioids. This analysis of clinical routine data evaluated the benefit of this treatment for patients previously receiving oral long-term treatment with weak opioids alone. Data of 310 patients previously treated with tramadol or tildate/naloxone and part of a multicentre observational study with 3295 patients were analyzed. In 89.7% of the 310 patients oral treatment with weak opioids was replaced by the 7-day buprenorphine patch due to insufficient analgesia. During treatment with the 7-day buprenorphine patch there was a clinically significant decrease of the mean pain intensity at rest during the day from 5.7 to 2.9, on physical effort during the day from 7.3 to 3.8 and at night from 5.2 to 2.3 (11-point NRS scale, p < or = 0.001). In addition, quality of life aspects such as mobility, self-reliance and quality of sleep improved, which are relevant for individual patient satisfaction with pain management. For patients with previous long-term tramadol or tilidate/naloxone treatment the switch to the 7-day buprenorphine matrix patch proved to be effective and safe for the management of chronic pain. The user-friendly 7-day application interval contributes to improving compliance and a reducing exposure to tablets.
Asunto(s)
Analgésicos Opioides/administración & dosificación , Buprenorfina/administración & dosificación , Naloxona/administración & dosificación , Dolor/tratamiento farmacológico , Tilidina/administración & dosificación , Tramadol/administración & dosificación , Actividades Cotidianas/clasificación , Administración Cutánea , Anciano , Anciano de 80 o más Años , Analgésicos Opioides/efectos adversos , Buprenorfina/efectos adversos , Enfermedad Crónica , Sustitución de Medicamentos , Femenino , Alemania , Humanos , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Naloxona/efectos adversos , Dimensión del Dolor/efectos de los fármacos , Estudios Prospectivos , Calidad de Vida , Tilidina/efectos adversos , Tramadol/efectos adversosRESUMEN
AIM: To obtain information on the efficacy, tolerability and safetyofa transdermal buprenorphine patch (Transtec PRO) in patients with moderate to severe chronic pain. In addition it should be evaluated to what extent the two fixed patch change days per weekare simplifyingthe therapy. METHODS: In this prospective multi-center post marketing surveillance study patients with chronic cancer and non-cancer pain were treated with transdermal buprenorphine for up to eight weeks. The evaluation included pain intensity, the dosage of the applied analgesics and additional therapies, the renal function (by serum creatinine) and adverse events. RESULTS: 3654 patients were treated for a mean of 50.4 days. Using the NRS-11 the mean pain intensity decreased from 6.3 at the time when patients were switched to the transdermal buprenorphine patch to 2.6 at the last treatment evaluation. The matrix patch was safe and well tolerated also in patients with advanced renal insufficiency. Adverse events were reported in 6.7% of the patients. 89.3% of the physicians quoted to prefer transdermal buprenorphine with the two fixed patch change days per week compared to the pre-treatment. CONCLUSION: The buprenorphine-containing matrix patch was effective and well tolerated in patients with moderate to severe chronic cancer and noncancer pain. From the physicians view the two fixed patch change days per week facilitate the guidance of therapy. In patients with advanced renal insufficiency a dose adjustment is not necessary.